Date: 2012-10-25
Type of information: Grant
Company: AMP Therapeutics (Germany)
Investors: SAB State Bank of Saxony (Germany)
Amount: € 1.7 million
Funding type: grant
Planned used: The funds will be used to support AMPT’s R&D programs. In particular, the financing will support the development of AMPT’S product pipeline, including lead compounds developed from antimicrobial peptides found in insects such as the honeybee and certain bugs.
Others: AMP Therapeutics has been awarded an R&D grant from the SAB State Bank of Saxony. In a joint project with the University of Leipzig titled “Use of antimicrobial peptides as new chemotherapy agents” the partners will collaborate on this project with a total cost volume of € 1.9 m. The non-repayable grant provided by the SAB makes up € 1.7 m of the total sum.
Therapeutic area: Infectious diseases
